Drug Profile
Research programme: therapeutics - Fred Hutchinson Cancer Research Center/University of Washington/Takeda
Latest Information Update: 28 Mar 2022
Price :
$50
*
At a glance
- Originator Fred Hutchinson Cancer Research Center; Takeda; University of Washington
- Class Antineoplastics; Neuroprotectants
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Gastrointestinal disorders; Neurological disorders
Most Recent Events
- 28 Mar 2022 No recent reports of development identified for research development in Cancer in USA
- 28 Mar 2022 No recent reports of development identified for research development in Gastrointestinal-disorders in USA
- 28 Mar 2022 No recent reports of development identified for research development in Neurological-disorders in USA